QQQ   269.09 (-0.45%)
AAPL   445.94 (-1.10%)
MSFT   206.55 (-0.82%)
FB   264.92 (+0.73%)
GOOGL   1,498.05 (+0.08%)
AMZN   3,146.88 (-0.04%)
NVDA   441.36 (-1.17%)
CGC   17.54 (-2.18%)
BABA   252.23 (+1.65%)
TSLA   1,405.29 (-0.94%)
GE   6.87 (+3.00%)
MU   48.71 (-0.90%)
AMD   79.64 (-3.16%)
T   30.49 (+0.96%)
F   7.29 (+2.82%)
ACB   10.07 (-1.47%)
GILD   68.67 (+0.23%)
NFLX   477.77 (-1.16%)
DIS   131.75 (+2.30%)
BAC   27.33 (+2.90%)
BA   185.59 (+3.44%)
QQQ   269.09 (-0.45%)
AAPL   445.94 (-1.10%)
MSFT   206.55 (-0.82%)
FB   264.92 (+0.73%)
GOOGL   1,498.05 (+0.08%)
AMZN   3,146.88 (-0.04%)
NVDA   441.36 (-1.17%)
CGC   17.54 (-2.18%)
BABA   252.23 (+1.65%)
TSLA   1,405.29 (-0.94%)
GE   6.87 (+3.00%)
MU   48.71 (-0.90%)
AMD   79.64 (-3.16%)
T   30.49 (+0.96%)
F   7.29 (+2.82%)
ACB   10.07 (-1.47%)
GILD   68.67 (+0.23%)
NFLX   477.77 (-1.16%)
DIS   131.75 (+2.30%)
BAC   27.33 (+2.90%)
BA   185.59 (+3.44%)
QQQ   269.09 (-0.45%)
AAPL   445.94 (-1.10%)
MSFT   206.55 (-0.82%)
FB   264.92 (+0.73%)
GOOGL   1,498.05 (+0.08%)
AMZN   3,146.88 (-0.04%)
NVDA   441.36 (-1.17%)
CGC   17.54 (-2.18%)
BABA   252.23 (+1.65%)
TSLA   1,405.29 (-0.94%)
GE   6.87 (+3.00%)
MU   48.71 (-0.90%)
AMD   79.64 (-3.16%)
T   30.49 (+0.96%)
F   7.29 (+2.82%)
ACB   10.07 (-1.47%)
GILD   68.67 (+0.23%)
NFLX   477.77 (-1.16%)
DIS   131.75 (+2.30%)
BAC   27.33 (+2.90%)
BA   185.59 (+3.44%)
QQQ   269.09 (-0.45%)
AAPL   445.94 (-1.10%)
MSFT   206.55 (-0.82%)
FB   264.92 (+0.73%)
GOOGL   1,498.05 (+0.08%)
AMZN   3,146.88 (-0.04%)
NVDA   441.36 (-1.17%)
CGC   17.54 (-2.18%)
BABA   252.23 (+1.65%)
TSLA   1,405.29 (-0.94%)
GE   6.87 (+3.00%)
MU   48.71 (-0.90%)
AMD   79.64 (-3.16%)
T   30.49 (+0.96%)
F   7.29 (+2.82%)
ACB   10.07 (-1.47%)
GILD   68.67 (+0.23%)
NFLX   477.77 (-1.16%)
DIS   131.75 (+2.30%)
BAC   27.33 (+2.90%)
BA   185.59 (+3.44%)
Log in

NYSEAMERICAN:PFNXPfenex Stock Price, Forecast & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume340,426 shs
Average Volume323,995 shs
Market Capitalization$253.57 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Pfenex Inc., a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidates include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that have completed Phase Ia clinical study. The company also develops PF582, a biosimilar candidate to Lucentis; PF529, a biosimilar to Neulasta; and hematology/oncology products, including PF743, a recombinant crisantaspase, as well as PF745, a recombinant crisantaspase with half-life extension technology. In addition, it has license and supply agreements for CRM197, a non-toxic mutant of diphtheria toxin. Pfenex Inc. is headquartered in San Diego, California.
Read More
Pfenex logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.16 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:PFNX
Previous SymbolNYSEMKT:PFNX
CUSIPN/A
CIKN/A
Phone+1-858-3524400

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees71
Market Cap$253.57 million
Next Earnings Date11/5/2020 (Estimated)
OptionableOptionable
30 days | 90 days | 365 days | Advanced Chart

Receive PFNX News and Ratings via Email

Sign-up to receive the latest news and ratings for PFNX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Pfenex (NYSEAMERICAN:PFNX) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Pfenex?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pfenex in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Pfenex
.

When is Pfenex's next earnings date?

Pfenex is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Pfenex
.

How were Pfenex's earnings last quarter?

Pfenex Inc (NYSEAMERICAN:PFNX) announced its earnings results on Thursday, August, 6th. The biotechnology company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.27) by $0.03.
View Pfenex's earnings history
.

What price target have analysts set for PFNX?

5 brokerages have issued 12 month price targets for Pfenex's stock. Their forecasts range from $13.00 to $20.00. On average, they expect Pfenex's stock price to reach $16.75 in the next twelve months.
View analysts' price targets for Pfenex
.

Has Pfenex been receiving favorable news coverage?

News articles about PFNX stock have trended neutral recently, according to InfoTrie. The research group identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Pfenex earned a news impact score of 0.2 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days.
View the latest news about Pfenex
.

Are investors shorting Pfenex?

Pfenex saw a increase in short interest in the month of February. As of February 15th, there was short interest totaling 1,040,000 shares, an increase of 32.2% from the January 31st total of 786,800 shares. Based on an average trading volume of 320,000 shares, the short-interest ratio is currently 3.3 days.
View Pfenex's Short Interest
.

Who are some of Pfenex's key competitors?

What other stocks do shareholders of Pfenex own?

Who are Pfenex's key executives?

Pfenex's management team includes the following people:
  • Mr. Evert B. Schimmelpennink, CEO, Pres, Sec. & Director (Age 47)
  • Ms. Patricia Lady C.M.A., CPA, M.B.A., CPA, MBA CMA, Chief Accounting Officer (Age 61)
  • Mr. Patrick K. Lucy, Chief Bus. Officer (Age 51)
  • Dr. Hubert C. Chen, Advisor (Age 50)
  • Ms. Susan A. Knudson, Chief Financial Officer (Age 55)

What is Pfenex's stock symbol?

Pfenex trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PFNX."

Who are Pfenex's major shareholders?

Pfenex's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Russell Investments Group Ltd. (0.42%), Cadence Capital Management LLC (0.36%), Strs Ohio (0.18%), UBS Group AG (0.06%), SG Americas Securities LLC (0.06%) and Delta Investment Management LLC (0.05%). Company insiders that own Pfenex stock include Evert B Schimmelpennink, Patrick K Lucy, Phillip M Schneider and Robin Campbell.
View institutional ownership trends for Pfenex
.

Which institutional investors are selling Pfenex stock?

PFNX stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Falcon Point Capital LLC, Delta Investment Management LLC, and UBS Group AG.
View insider buying and selling activity for Pfenex
.

Which institutional investors are buying Pfenex stock?

PFNX stock was acquired by a variety of institutional investors in the last quarter, including Creative Planning, SG Americas Securities LLC, Cadence Capital Management LLC, and Strs Ohio. Company insiders that have bought Pfenex stock in the last two years include Evert B Schimmelpennink, Phillip M Schneider, and Robin Campbell.
View insider buying and selling activity for Pfenex
.

How do I buy shares of Pfenex?

Shares of PFNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

How big of a company is Pfenex?

Pfenex has a market capitalization of $0.00. Pfenex employs 71 workers across the globe.

What is Pfenex's official website?

The official website for Pfenex is www.pfenex.com.

How can I contact Pfenex?

Pfenex's mailing address is 10790 Roselle St, SAN DIEGO, CA 92121-1508, United States. The biotechnology company can be reached via phone at +1-858-3524400.

This page was last updated on 8/11/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.